Cytokines, Chemokines & Receptors

Cat. No.

AT1495

CAS No.

1476039-58-3

Nemolizumab

Synonyms: CIM331

Nemolizumab (CIM331) is a humanized monoclonal antibody designed to selectively target the interleukin-31 receptor alpha (IL-31RA). By binding to IL-31RA, Nemolizumab effectively inhibits the interaction between interleukin-31 (IL-31) and its receptor, thereby blocking the downstream signaling pathways. This inhibition is clinically relevant as it contributes to the reduction of pruritus (itching) and sleep disturbances associated with various dermatological conditions, including atopic dermatitis (AD). Nemolizumab is currently under investigation for its therapeutic potential and efficacy in treating symptoms of AD and related conditions.

Cat. No.

AT1500

CAS No.

2173054-79-8

Astegolimab

Synonyms: MSTT 1041A; RG 6149

Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody designed to inhibit IL-33 signaling through specific binding to ST2, the receptor for IL-33. This antibody is primarily explored for its therapeutic potential in studies related to chronic obstructive pulmonary disease (COPD), offering a targeted approach to modulate immune responses implicated in this condition.

Cat. No.

AT1505

CAS No.

241473-69-8

Reslizumab

Synonyms: Sch 55700

Reslizumab (Sch 55700) is a humanized monoclonal antibody designed to specifically target and neutralize interleukin-5 (IL-5), a key cytokine involved in the pathogenesis of eosinophilic asthma. This antibody exhibits a high binding affinity for human IL-5, demonstrating dissociation constants (K_D) of 109 pM and 4.3 pM in Biacore surface plasmon resonance and Kinetic Exclusion Assay analyses, respectively. By inhibiting the activity of IL-5, Reslizumab effectively reduces the growth and survival of eosinophils, thereby mitigating the inflammatory processes associated with eosinophilic asthma. This makes Reslizumab a critical tool in the therapeutic management of this condition.

Cat. No.

AT1507

CAS No.

1439393-01-7

AMG-811

AMG-811 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets interferon-gamma (IFNγ), a key cytokine in the regulation of immune responses. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT1519

CAS No.

1194585-53-9

Sirukumab

Synonyms: CNTO-136

Sirukumab (CNTO-136) is a humanized monoclonal IgG1κ antibody targeting IL-6 (Interleukin-6). By binding to IL-6, Sirukumab inhibits IL-6-mediated signal transduction, effectively preventing the activation of transcriptional activators involved in inflammatory responses. This blockade curtails the downstream biological effects associated with IL-6 activity. Sirukumab is primarily utilized in research focused on active lupus nephritis and rheumatoid arthritis, offering significant insights into the pathophysiology and potential therapeutic interventions for these conditions.

Cat. No.

AT1522

CAS No.

948570-30-7

Rontalizumab

Synonyms: RhuMab IFNalpha; Anti-Human IFN alpha Recombinant Antibody

Rontalizumab is a humanized IgG1 monoclonal antibody that specifically targets interferon-alpha (IFN-α). This antibody is utilized primarily in research focused on systemic lupus erythematosus, aiding in the exploration of therapeutic avenues and mechanistic insights into the disease.

Cat. No.

AT1525

CAS No.

196078-29-2

Mepolizumab

Synonyms: SB 240563

Mepolizumab (SB 240563) is a humanized monoclonal antibody designed to specifically bind to and neutralize interleukin-5 (IL-5). IL-5 is a critical cytokine that regulates eosinophil proliferation, activation, and survival. This antibody is utilized in research focused on eosinophilic conditions, including eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for these diseases.

Cat. No.

AT1533

CAS No.

2923284-67-5

GSK-1070806

Synonyms: Aletekitug

GSK-1070806 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-18 (IL-18). This antibody is comprised of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, with a predicted molecular weight of 147.38 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa, Isotype Control. GSK-1070806 serves as a valuable tool for the study of IL-18's role in inflammatory responses and immune regulation, making it applicable in research focused on autoimmune diseases and cytokine regulation.

Cat. No.

AT1535

CAS No.

1416147-64-2

Dapirolizumab

Dapirolizumab is a monoclonal antibody specifically designed to target and bind to CD40 ligand (CD40L), effectively blocking its interaction with CD40 receptors on the surface of immune cells. This interaction is crucial for the activation of the adaptive immune response. By inhibiting this pathway, Dapirolizumab helps to modulate immune system activity and has been shown to attenuate the symptoms of systemic lupus erythematosus. This antibody is applicable in research focused on the pathogenesis and treatment of autoimmune diseases, particularly those involving aberrant CD40-CD40L signaling.

Cat. No.

AT1546

CAS No.

909875-08-7

Enokizumab

Synonyms: MEDI-528

Enokizumab (MEDI-528) is a monoclonal antibody specifically designed to target interleukin-9 (IL-9). IL-9 plays a critical role in regulating various pathological processes in the respiratory system, including airway inflammation, mucus production, airway hyperresponsiveness, and fibrosis. This regulation is primarily mediated through the proliferation and activation of mast cells within the airways. Enokizumab's mechanism of action focuses on neutralizing IL-9, thereby potentially mitigating its effects on these respiratory conditions. This antibody is pivotal for research focused on the pathophysiology of respiratory diseases and the development of targeted therapies.

Cat. No.

AT1560

Anti-CXCL4/PF4 Antibody

The Anti-CXCL4/PF4 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the CXCL4/PF4 protein. This antibody comprises a human IgG4SP type heavy chain and a human kappa type light chain, with an estimated molecular weight of 144.5 kDa. For experimental control purposes, the Human IgG4 kappa Isotype Control is recommended. This antibody is ideal for research applications focusing on the biological roles and regulatory mechanisms of the CXCL4/PF4 chemokine in inflammation and coagulation processes.